JPRN-jRCT2080221153未知3 期
Open, Long-Term Safety Study With Vildagliptin in Patients With Type 2 Diabetes (as add-on therapy with metformin, thiazolidinedione, alpha-glucosidase inhibitor or rapid-acting insulin secretagogues)
ovartis Pharma K.K.0 个研究点目标入组 216 人开始时间: 2010年7月8日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 216
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients with type 2 diabetes inadequately controlled with diet, exercise and metformin, thiazolidinedione, or alpha-GI, or glinides monotherapy
- •- Age in the 20 years or over inclusive
- •- HbA1c in the range of >= 6.5 to =< 10%
排除标准
- •- Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
- •- Significant heart diseases
- •- Significant diabetic complications
研究者
相似试验
未知
3 期
ong-term safety study of vildagliptin in patients with type 2 diabetesType 2 DiabetesJPRN-jRCT2080220245ovartis Pharma K.K.150
已完成
不适用
Efficacy and Safety of Vildagliptin in Type 2 DiabetesCTRI/2022/01/039112Cipla Limited1,691
未知
1 期
To Assess the Efficacy and Safety of Vildagliptin in Patients with Type 2 DiabetesType 2 DiabetesJPRN-jRCT2080220150ovartis Pharma K.K.264
未知
3 期
To assess the efficacy and safety of vildagliptin as add-on therapy to sulfonylurea in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapyType 2 DiabetesJPRN-jRCT2080220244ovartis Pharma K.K.200
招募中
4 期
An study to assess the safety and efficacy of vildagliptin vs voglibose in management of post-prandial blood sugar in patients with T2DMCTRI/2024/08/072355Dr Mahima V